{"disease":{"id":"systemic-mastocytosis","name":"systemic mastocytosis"},"drugs":{"marketed":[{"drug_id":"midostaurin","indication_name":"Aggressive systemic mastocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rydapt","generic_name":"MIDOSTAURIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Mast/stem cell growth factor receptor Kit","drug_class":"Kinase Inhibitor [EPC]","quality_score":62,"revenue":"200","mechanism":"Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells."},{"drug_id":"chembl-chembl941","indication_name":"Aggressive Systemic Mastocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"part-c-met097","indication_name":"Treatment of Systemic Mastocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"part-c-met097","indication_name":"Treatment of Aggressive Systemic Mastocytosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06210698","title":"Angioedema Biomarker Research Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Foundation For Rare Disease Research","has_results":false},{"nct_id":"NCT07142473","title":"Mastocytosis From Pediatric Age to Adulthood: Local Registry of Cutaneous and Systemic Mastocytosis","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT04910685","title":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":534,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04695431","title":"Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM","phase":"","overall_status":"COMPLETED","enrollment_count":317,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03731260","title":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05504408","title":"Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07264959","title":"An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT04655118","title":"Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":121,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT03580655","title":"(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT02561988","title":"(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT07255638","title":"A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03632811","title":"Adaptation of the Questionnaire \"Regarding Patient's Quality of Life With Mastocytosis\" in the French Language","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT03401060","title":"Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03770273","title":"Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04681105","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03214666","title":"GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"GT Biopharma, Inc.","has_results":true},{"nct_id":"NCT05609942","title":"Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT03739606","title":"Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05219266","title":"Managed Access Programs for PKC412, Midostaurin","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":19},"guidelines":[],"source":"Drug Landscape verified database"}